Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ELDN 
Eledon Pharmaceuticals Inc (ELDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ELDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -87.49% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 200.60M USD | Price to earnings Ratio - | 1Y Target Price 10.4 |
Price to earnings Ratio - | 1Y Target Price 10.4 | ||
Volume (30-day avg) 224952 | Beta 0.81 | 52 Weeks Range 1.52 - 5.54 | Updated Date 03/30/2025 |
52 Weeks Range 1.52 - 5.54 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.3267 | Actual -0.9456 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.11% | Return on Equity (TTM) -57.73% |
Valuation
Trailing PE - | Forward PE 5.39 | Enterprise Value 61379946 | Price to Sales(TTM) - |
Enterprise Value 61379946 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.84 | Shares Outstanding 59881800 | Shares Floating 46043696 |
Shares Outstanding 59881800 | Shares Floating 46043696 | ||
Percent Insiders 1.4 | Percent Institutions 68.18 |
Analyst Ratings
Rating 4.83 | Target Price 12.5 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eledon Pharmaceuticals Inc
Company Overview
History and Background
Eledon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. The company was incorporated as Tolerion, Inc. in 2009 and later changed its name to Eledon Pharmaceuticals, Inc. in 2020. Its focus has evolved to address unmet needs in areas like organ transplantation and inflammatory bowel diseases.
Core Business Areas
- Pharmaceutical Development: Focuses on developing novel immunotherapies for autoimmune and inflammatory diseases, including those affecting organ transplantation.
Leadership and Structure
Eledon is led by a management team with experience in drug development and commercialization. The company's structure includes departments focused on research, clinical development, regulatory affairs, and business operations.
Top Products and Market Share
Key Offerings
- TOL101: TOL101 is Eledon's lead investigational therapy, a fusion protein designed to modulate the CD3 receptor on T cells to prevent inflammation and autoimmune reactions. TOL101 is in Phase 2 clinical trials for prevention of islet allograft rejection in patients undergoing transplantation for type 1 diabetes. Competitors include companies developing alternative immunosuppressants and cell therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on autoimmune and inflammatory diseases is large and competitive, with substantial unmet medical needs and potential for innovative therapies. The transplantation segment is driven by demand for organs and the need for better immunosuppression regimens.
Positioning
Eledon aims to differentiate itself through its CD3 modulation approach, potentially offering a more targeted and safer alternative to traditional immunosuppressants. It is focused on specific niches within the larger autoimmune/inflammatory disease landscape.
Total Addressable Market (TAM)
The total addressable market for autoimmune and inflammatory diseases is in the billions of dollars annually. Eledon is positioned to capture a share of this market by focusing on transplantation and specific indications with high unmet need.
Upturn SWOT Analysis
Strengths
- Novel CD3 modulation technology platform
- Lead asset in Phase 2 clinical development
- Experienced management team
Weaknesses
- Limited financial resources
- Single lead asset creates risk
- Dependence on clinical trial success
Opportunities
- Positive clinical trial results could attract partnerships or acquisition
- Expansion into additional indications
- Advancements in drug delivery technologies
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- NVS
- BMY
- SNY
- GILD
Competitive Landscape
Eledon is a smaller player in a highly competitive field dominated by large pharmaceutical companies. Its advantage lies in its novel technology and focus on specific unmet needs. However, it faces challenges in competing for resources and market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by advancing TOL101 through clinical trials and securing financing.
Future Projections: Future growth depends on successful clinical trial outcomes, potential partnerships, and regulatory approvals. Analyst estimates vary widely due to the inherent uncertainty in drug development.
Recent Initiatives: Recent initiatives include enrolling patients in the Phase 2 clinical trial of TOL101 and exploring potential new indications.
Summary
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company with a novel technology platform. Its strength lies in its innovative approach to modulating the CD3 receptor. Success hinges on the outcomes of clinical trials for TOL101, and the company must address challenges related to funding and competition from larger pharmaceutical players. Positive results in clinical trials and securing partnerships would be essential for future growth and market penetration.
Similar Companies
- NVS
- BMY
- SNY
- GILD
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eledon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2014-09-17 | CEO & Non Independent Director Dr. David-Alexandre C. Gros M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://eledon.com |
Full time employees 31 | Website https://eledon.com | ||
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.